home > ebr

European Biopharmaceutical Review


European Biopharmaceutical Review (EBR) is a journal designed to fill a unique position in scientific publishing. Published quarterly, it provides a dedicated platform of communication and information for the European biopharmaceutical market across Europe, North America & the rest of the world.

With editorial consisting of in-depth articles, case studies, meeting and report reviews written by specialists with hands-on experience in the biopharmaceutical industry, traditional multi-national pharmaceutical companies, investment houses and industry-associated governmental, economic and societal bodies. Each quarterly edition examines topical areas of importance across the board of biopharmaceutical research and development, with regular feature sections on BioBusiness Development, Research and Innovation, BioDiscovery, BioManufacturing plus special focuses on geographic or therapeutic territories.

For further information please contact:


David Hirsh



Emma Naks

Connect with us on Twitter: follow @EBRmagazine

Read our publications on the go in the Samedan app for iPhone and iPad. You can download issues for offline reading and our archives go as far back as 2008! Download for free on the App Store.

View the
digital version
of EBR

Featured in this issue
In Brief

In the Lead

Industry advisor Emile Bellott examines the biosimilar market, noting the enthusiasm of European and Asian regulators, as well as commenting on what the future holds for the US.
BioResearch and Innovation
In Vitro Testing

Super Models

Kirkstall’s J Malcolm Wilkinson
and Kelly S Davidge examine in vitro alternatives to animal testing. Although generally restricted to niche uses in academia, these more representative and complex models could one day be utilised in commercial drug development.
  Discovery Technology
Drug Repositioning

Same Drug: New Purpose

Repositioning has been used to speed up productivity issues in current drug development and address unmet patient needs. José Manuel Mas and Judith Farrés from Anaxomics take us through a few key approaches.

Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd
Published quarterly in
January, April,
July and October
Banner of CMCBio on Samedan
Banner of Wacker 1 on Samedan
Industry Events


29 September - 1 October 2015, Hilton Hotel, Algiers (Algeria)

MAGHREB PHARMA Expo is the largest pharmaceutical technology tradeshow in Africa
More info >>

News and Press Releases

Helping Nepal – SHL To Match Staff Donations

In immediate response to the devastating earthquake that left Nepal in ruins on April 25th, SHL quickly reached out to World Vision to hold an internal donation event at its key manufacturing sites in Taiwan where a booth is being set up for staff to contribute in any amount possible.
More info >>

Banner of Genome Editing Applications on Samedan
air transport logo


White Papers

Translating Cancer Genomics Into A Personalised Approach For Cancer Patients

PRA Health Sciences (PRA)

Over the past few decades, the approach to prevention, diagnosis and treatment of cancer has radically shifted from organ-based to morphology-based and most recently, to genetics-based. Personalized or precision medicine (tailoring a treatment for a patient’s particular disease at a precise time point) is being performed every day at different levels in the clinical setting.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement